» Articles » PMID: 29108360

Prediction of Radio-responsiveness with Immune-profiling in Patients with Rectal Cancer

Overview
Journal Oncotarget
Specialty Oncology
Date 2017 Nov 8
PMID 29108360
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

We evaluate whether the tumor immune infiltrate (TIL) could be used for prediction of responsiveness to preoperative chemoradiotherapy (PCRT) in rectal cancers. Using formalin-fixed paraffin-embedded slides of pretreatment biopsies, co-stain for CD4, CD8, CD274 (PD-L1), FOXP3, cytokeratin, and DAPI was performed with (Perkin-Elmer, Waltham, MA). Multispectral imaging and digital analysis to visualize and quantify specific immune infiltrates were performed using the (Perkin-Elmer). The density (number of cells per mm) and proportion of total TILs and specific cell types in the stroma were calculated by inForm™ 2.2.1 software (Perkin-Elmer). The density and proportion of total TILs and specific cell types in the stroma were calculated by inForm™ 2.2.1 software (Perkin-Elmer, Waltham, MA). Patients were classified as group with total regression (TR, = 25) and group with residual disease (near total, moderate, and minimal regression, RD, 50). The mean density of T cell infiltration and CD274 (PD-L1)+ lymphocyte were significantly higher in TR ( = 0.005, = 0.001). The proportion of CD4+ lymphocyte (p=0.042) and CD274 (PD-L1)+ lymphocyte ( = 0.002) were different between 2 groups. The TR group has lower CD4+ and higher CD274 (PD-L1)+ proportions than RD group. The ratio among CD4+, CD8+, CD274 (PD-L1)+, FOXP3+ T cell was different between groups. TR group showed lower CD4/ CD274 (PD-L1) ( = 0.007), CD8/ CD274 (PD-L1) ( = 0.02), and FOXP3/ CD274 (PD-L1) ( = 0.003) ratio than RD group. The determination of the immune infiltrate in biopsies before treatment could be a valuable information for the prediction of responsiveness to PCRT.

Citing Articles

Tumor Immune Microenvironment Biomarkers for Recurrence Prediction in Locally Advanced Rectal Cancer Patients after Neoadjuvant Chemoradiotherapy.

Hwang J, Kim S, Bang H, Kim H, Shim H, Bae W Cancers (Basel). 2024; 16(19).

PMID: 39409972 PMC: 11475605. DOI: 10.3390/cancers16193353.


An immune-related gene prognostic prediction risk model for neoadjuvant chemoradiotherapy in rectal cancer using artificial intelligence.

Shu P, Liu N, Luo X, Tang Y, Chen Z, Li D Front Oncol. 2024; 14:1294440.

PMID: 38406803 PMC: 10889124. DOI: 10.3389/fonc.2024.1294440.


CD11c and IRF8 cell densities in rectal cancer biopsies predict outcomes of neoadjuvant chemoradiotherapy.

Tse B, Bergamin S, Steffen P, Hruby G, Pavlakis N, Clarke S Oncoimmunology. 2023; 12(1):2238506.

PMID: 37485033 PMC: 10361136. DOI: 10.1080/2162402X.2023.2238506.


Immune Response and Immune Checkpoint Molecules in Patients with Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Review.

Koukourakis I, Platoni K, Tiniakos D, Kouloulias V, Zygogianni A Curr Issues Mol Biol. 2023; 45(5):4495-4517.

PMID: 37232754 PMC: 10216994. DOI: 10.3390/cimb45050285.


Spatial and Quantitative Analysis of Tumor-Associated Macrophages: Intratumoral CD163-/PD-L1+ TAMs as a Marker of Favorable Clinical Outcomes in Triple-Negative Breast Cancer.

Shinohara H, Kobayashi M, Hayashi K, Nogawa D, Asakawa A, Ohata Y Int J Mol Sci. 2022; 23(21).

PMID: 36362023 PMC: 9656504. DOI: 10.3390/ijms232113235.


References
1.
Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C . Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012; 30(16):1926-33. DOI: 10.1200/JCO.2011.40.1836. View

2.
Joye I, Deroose C, Vandecaveye V, Haustermans K . The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review. Radiother Oncol. 2014; 113(2):158-65. DOI: 10.1016/j.radonc.2014.11.026. View

3.
Pilones K, Vanpouille-Box C, Demaria S . Combination of radiotherapy and immune checkpoint inhibitors. Semin Radiat Oncol. 2014; 25(1):28-33. DOI: 10.1016/j.semradonc.2014.07.004. View

4.
Huh J, Lee J, Kim H . Pretreatment expression of 13 molecular markers as a predictor of tumor responses after neoadjuvant chemoradiation in rectal cancer. Ann Surg. 2013; 259(3):508-15. DOI: 10.1097/SLA.0b013e31829b3916. View

5.
Watanabe T, Kobunai T, Akiyoshi T, Matsuda K, Ishihara S, Nozawa K . Prediction of response to preoperative chemoradiotherapy in rectal cancer by using reverse transcriptase polymerase chain reaction analysis of four genes. Dis Colon Rectum. 2013; 57(1):23-31. DOI: 10.1097/01.dcr.0000437688.33795.9d. View